These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36065795)

  • 21. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
    Cavallari LH; Groo VL; Viana MA; Dai Y; Patel SR; Stamos TD
    Pharmacotherapy; 2010 Jan; 30(1):1-9. PubMed ID: 20030467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study.
    Thomsen RW; Nicolaisen SK; Hasvold P; Garcia-Sanchez R; Pedersen L; Adelborg K; Egfjord M; Egstrup K; Sørensen HT
    J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29789332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
    Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
    Rossignol P; Williams B; Mayo MR; Warren S; Arthur S; Ackourey G; White WB; Agarwal R
    Eur J Heart Fail; 2020 Aug; 22(8):1462-1471. PubMed ID: 32452085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Savarese G; Xu H; Trevisan M; Dahlström U; Rossignol P; Pitt B; Lund LH; Carrero JJ
    JACC Heart Fail; 2019 Jan; 7(1):65-76. PubMed ID: 30553905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
    Trevisan M; de Deco P; Xu H; Evans M; Lindholm B; Bellocco R; Barany P; Jernberg T; Lund LH; Carrero JJ
    Eur J Heart Fail; 2018 Aug; 20(8):1217-1226. PubMed ID: 29667759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
    Ferreira JP; Verdonschot J; Wang P; Pizard A; Collier T; Ahmed FZ; Brunner-La-Rocca HP; Clark AL; Cosmi F; Cuthbert J; Díez J; Edelmann F; Girerd N; González A; Grojean S; Hazebroek M; Khan J; Latini R; Mamas MA; Mariottoni B; Mujaj B; Pellicori P; Petutschnigg J; Pieske B; Rossignol P; Rouet P; Staessen JA; Cleland JGF; Heymans S; Zannad F;
    JACC Heart Fail; 2021 Apr; 9(4):268-277. PubMed ID: 33549556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
    Kobayashi M; Huttin O; Ferreira JP; Duarte K; González A; Heymans S; Verdonschot JAJ; Brunner-La Rocca HP; Pellicori P; Clark AL; Petutschnigg J; Edelmann F; Cleland JG; Rossignol P; Zannad F; Girerd N;
    Eur J Heart Fail; 2023 Aug; 25(8):1284-1289. PubMed ID: 37062878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
    Ferreira JP; Collier T; Clark AL; Mamas MA; Rocca HB; Heymans S; González A; Ahmed FZ; Petutschnigg J; Mujaj B; Cuthbert J; Rouet P; Pellicori P; Mariottoni B; Cosmi F; Edelmann F; Thijs L; Staessen JA; Hazebroek M; Verdonschot J; Rossignol P; Girerd N; Cleland JG; Zannad F
    Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):149-156. PubMed ID: 33822033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing potassium levels in critically ill patients with heart failure: application of a group-based trajectory model.
    Lin Z; Zheng J; Liu X; Hu X; Fuxian R; Gao D
    ESC Heart Fail; 2023 Feb; 10(1):57-65. PubMed ID: 36151847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
    Verdonschot JAJ; Ferreira JP; Pellicori P; Brunner-La Rocca HP; Clark AL; Cosmi F; Cuthbert J; Girerd N; Mariottoni B; Petutschnigg J; Rossignol P; Cleland JGF; Zannad F; Heymans SRB;
    Cardiovasc Diabetol; 2021 Aug; 20(1):163. PubMed ID: 34372849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.
    Ferreira JP; Girerd N; Medeiros PB; Santos M; Carvalho HC; Bettencourt P; Kénizou D; Butler J; Zannad F; Rossignol P
    Clin Res Cardiol; 2016 Jun; 105(6):489-507. PubMed ID: 26615605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of dyskalemia at admission and early dyskalemia correction on survival and cardiac events of critically ill patients.
    Bouadma L; Mankikian S; Darmon M; Argaud L; Vinclair C; Siami S; Garrouste-Orgeas M; Papazian L; Cohen Y; Marcotte G; Styfalova L; Reignier J; Lautrette A; Schwebel C; Timsit JF;
    Crit Care; 2019 Dec; 23(1):415. PubMed ID: 31856891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL.
    Ferreira JP; Konstam M; Rossignol P; Kiernan MS; Zannad F
    J Card Fail; 2023 Jan; 29(1):45-52. PubMed ID: 36244652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
    Kobayashi M; Girerd N; Ferreira JP; Kevin D; Huttin O; González A; Bozec E; Clark AL; Cosmi F; Cuthbert J; Diez J; Edelmann F; Hazebroek M; Heymans S; Mariottoni B; Pellicori P; Petutschnigg J; Pieske B; Staessen JA; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F
    Eur J Heart Fail; 2022 Sep; 24(9):1559-1568. PubMed ID: 35703355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
    Ferreira JP; Claggett BL; Liu J; Desai AS; Pfeffer MA; Anand IS; van Veldhuisen DJ; Kober L; Cleland JGF; Rouleau JL; Packer M; Zile MR; Shi VC; Lefkowitz MP; Shah SJ; Vardeny O; Zannad F; Solomon SD; McMurray JJV
    Eur J Heart Fail; 2021 May; 23(5):776-784. PubMed ID: 33609066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry.
    Crespo-Leiro MG; Barge-Caballero E; Segovia-Cubero J; González-Costello J; López-Fernández S; García-Pinilla JM; Almenar-Bonet L; de Juan-Bagudá J; Roig-Minguell E; Bayés-Genís A; Sanz-Julve M; Lambert-Rodríguez JL; Lara-Padrón A; Pérez-Ruiz JM; Fernández-Vivancos Marquina C; de la Fuente-Galán L; Varela-Román A; Torres-Calvo F; Andrés-Novales J; Escudero-González A; Pascual-Figal DA; Ridocci-Soriano F; Sahuquillo-Martínez A; Bierge-Valero D; Epelde-Gonzalo F; Gallego-Page JC; Dalmau González-Gallarza R; Bover-Freire R; Quiles-Granado J; Maggioni AP; Lund LH; Muñiz J; Delgado-Jiménez J
    Rev Esp Cardiol (Engl Ed); 2020 Apr; 73(4):313-323. PubMed ID: 31672562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.